There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > SLAMF7


SLAMF7 Molecule Information

Name:SLAM family member 7
Target Synonym:Novel Ly9;CS1;CD_antigen=CD319;Membrane protein FOAP-12;CRACC;SLAMF7;Protein 19A;SLAM family member 7;CD2 subset 1;CD2-like receptor-activating cytotoxic cells
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Approved

SLAMF7 Part of Bioactivity data

Human SLAMF7, Fc TagHuman SLAMF7, Fc Tag (Cat. No. SL7-H5256) ELISA bioactivity

Immobilized Human SLAMF7, Fc Tag (Cat. No. SL7-H5256) at 2 μg/mL (100 μL/well) can bind Humanized Anti-Human CS1 MAb with a linear range of 0.3-5 ng/mL (Routinely tested).

Biotinylated Human SLAMF7, Avitag,His TagBiotinylated Human SLAMF7, Avitag,His Tag (Cat. No. SL7-H82E0) ELISA bioactivity

Immobilized Humanized Anti-Human CS1 MAb at 1 μg/mL (100 μL/well) can bind Biotinylated Human SLAMF7, Avitag,His Tag (Cat. No. SL7-H82E0) with a linear range of 0.6-5 ng/mL (Routinely tested).

SLAMF7 Protein Product ListCompare or Buy

SLAMF7 Molecule Synonym Name


SLAMF7 Molecule Background

SLAM family member 7 (SLAMF7) is also known as CD2-like receptor-activating cytotoxic cells (CRACC), Membrane protein FOAP-12, CD antigen CD319, Novel Ly9, Protein 19A, which is a single-pass type I membrane protein and a member of the CD2 family of cell surface receptors. SLAMF7 is expressed in spleen, lymph node, peripheral blood leukocytes, bone marrow, small intestine, stomach, appendix, lung and trachea. Isoform 1 of SLAMF7 mediates NK cell activation through a SH2D1A-independent extracellular signal-regulated ERK-mediated pathway. May play a role in lymphocyte adhesion. Isoform 3 of SLAMF7 does not mediate any NK cell activation.

SLAMF7 References

SLAMF7 Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Elotuzumab HuLuc-63; BMS-901608; PDL-063  Approved Abbvie, Bristol-Myers Squibb EMPLICITI fda Multiple myeloma (MM) BRISTOL MYERS SQUIBB 2015-11-30 Multiple myeloma (MM) Details

SLAMF7 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
UCART-CS1 UCART-CS1; UCART-38 Phase Ⅰ Cellectis, M.D. Anderson Cancer Center Multiple myeloma (MM) Details
BCMA-CS1 cCAR T cell therapy (iCell Gene Therapeutics) Phase Ⅰ iCell Gene Therapeutics Multiple myeloma (MM) Details
Azintuxizumab vedotin ABBV-838 Phase Ⅰ Abbvie Multiple myeloma (MM) Details
CD319 chimeric antigen T cell therapy (Wuhan Bio Raid Biotechnology) Phase Not Specified Wuhan Bio-Raid Biotechnology, Tongji Hospital hematological malignancies Details

This web search service is supported by Google Inc.